The International Federation of Psoriasis Associations (IFPA) is a nonprofit organization uniting national and regional psoriasis associations from around the world. Since being founded in 1971, they have worked to resolve the international psoriasis community’s challenges. IFPA campaigns on behalf of all people with psoriasis and psoriatic arthritis. Their goals are to empower their members, improve living conditions for patients, raise awareness of psoriasis and psoriatic arthritis, and cooperate with fellow stakeholders.
The IPC and IFPA are currently working together on:
– Global Psoriasis Atlas (GPA)
– Recategorization of disease severity
– Telemedicine
– Skin of Color
The National Psoriasis Foundation (NPF) is a nonprofit organization in the United States dedicated to finding a cure for psoriasis and psoriatic arthritis. It serves as a resource for individuals affected by these conditions, providing support, education, and advocacy. The NPF conducts research, raises awareness, and works to improve access to effective treatments and healthcare for people living with psoriasis and psoriatic arthritis.
Officially founded in 1935, the International League of Dermatological Societies (ILDS) has been promoting skin health around the world for over 80 years. Its forerunner began in 1889 as the first of many World Congresses of Dermatology. Today, the ILDS represents dermatology at the highest level, with over 180 Member Societies from more than 80 countries, representing over 200,000 dermatologists. ILDS works closely with partners worldwide, including the World Health Organization (WHO), with whom ILDS is in official relations, to improve skin health for all people.
Founded in July 2008 in Buenos Aires, Argentina, SOLAPSO emerged as a visionary endeavor spearheaded by seasoned dermatologists passionate about advancing the understanding, diagnosis, and treatment of psoriasis. Their shared commitment to fostering the growth and dissemination of knowledge surrounding this condition in Latin America led to its official establishment as a civil association in November of the same year. Since then, SOLAPSO has played a pivotal role in promoting regional awareness through impactful events across various countries and valuable support for scientific publications, amplifying the knowledge surrounding psoriasis in Latin America.
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
